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Abstract
Primary spinal melanomas are extremely rare lesions. In 1906, Hirschberg reported the first primary spinal
melanoma, and since then only 40 new cases have been reported. A 47-year-old man was admitted suffering from
low back pain, fatigue and loss of body weight persisting for three months. He had a 17-year-old history of an
operated primary spinal melanoma from T7-T9, which had remained stable for these 17 years. Routine laboratory
findings and clinical symptoms aroused suspicion of a metastatic disease. Multislice computed tomography and
magnetic resonance imaging revealed stage-IV melanoma with thoracic, abdominal and skeletal metastases
without the recurrence of the primary process. Transiliac crest core bone biopsy confirmed the diagnosis of
metastatic melanoma. It is important to know that in all cases of back ore skeletal pain and unexplained weight
loss, malignancy must always be considered in the differential diagnosis, especially in the subjects with a positive
medical history. Patients who have back, skeletal, or joint pain that is unresponsive to a few weeks of conservative
treatment or have known risk factors with or without serious etiology, are candidates for imaging studies. The
present case demonstrates that complete surgical resection alone may result in a favourable outcome, but regular
medical follow-up for an extended period, with the purpose of an early detection of a metastatic disease, is highly
recommended.
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Background
Malignant melanoma is an aggressive tumour with a
variable prognosis: that depends on tumour site and the
extent of surgical resection. According to epidemiologi-
cal data, its annual incidence has increased significantly
in recent years [1]. Primary melanoma of the central
nervous system (CNS) is rare and accounts for approxi-
mately 1% of all cases of melanoma [2]. They are either
intradural, extradural or have both intra and extradural
components. However, primary spinal extradural mela-
noma is extremely rare [3]. It is a solitary lesion asso-
ciated with leptomeninges and neural crest, the tissue
source of its precursory melanocytes. In 1906, Hirsch-
berg reported the first primary spinal melanoma, and
s i n c et h e no n l y4 0n e wc a s e sh a v eb e e nr e p o r t e d[ 4 ] .
We present a case of primary thoracic extradural spinal
melanoma occurring with low back pain and metastatic
disease 17 years after the initial surgical resection.
Case presentation
In 1993, a 30-year-old man without accompanying
comorbidity, was hospitalized for a sudden bilateral
spastic paraparesis. General physical examination
revealed progressive bilateral lower extremity weakness
associated with hypoesthesia distal of the dermatome
level of T9. A plain myelography showed epidural block
of contrast flowing along the spinal canal from the level
of T7. Therefore, laminectomy was performed at the
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rally located tumour measuring 2.5 × 1 cm., without
infiltration of dura and spreading through vertebral fora-
mina. Histopathologic and immunohistochemical analy-
sis confirmed a malignant melanoma (Figure 1A and
1B). The patient did not receive any radiotherapy
because surgical resection appeared completely without
opening the dura. The patient was also subjected to
further clinical and oncological evaluation which did not
reveal any other melanoma lesions or metastases and
other primary process could not be established. With
these data and according to Hayward’s criteria [5], the
diagnosis of primary spinal melanoma was established.
He was discharged from the hospital in a good general
condition with the recommendation for a regular fol-
low-up and he was cleared disease-free a few years after
the operation without any need for specific oncological
treatment.
In 2010, 17 years later, the same patient was admitted
to our rheumatology department with a three-month
history of low back pain, fatigue and loss of body
weight. He was treated with medication and physiother-
apy, but his symptoms did not subside. Physical exami-
nation showed a right sacroiliac joint tenderness on
palpation with a positive Mennel’ss i g n ,L a s è g u e ’ss i g n
was bilaterally negative and the lumbar vertebral seg-
ment motility was very painful. In this period he had no
history of fever or pain in other joints, bones and mus-
cles. He did not notice any skin lesions and he didn’t
have any other problems other than the above. The
stool and urine were normal. General physical examina-
tion revealed no signs of lymphadenopathy, splenome-
galy, hepatomegaly or other abnormalities. Routine
laboratory tests showed anemia (hemoglobin 102 g/L,
range 138-175), thrombocytosis (641 × 10
9/L, range
158-424), low serum iron concentration (3 μmol/L,
range 8-30), high serum ferritin concentration (790 μg/
L, range 15-150), high serum lactate-dehydrogenase
activity (745 U/L, range 1-241) and high erythrocyte
sedimentation rate (96 mm/h, range 3-23). Further
laboratory studies and blood chemistry including serum
glucose level, alkaline phosphatase, renal and hepatic
parameters, electrolytes, protein electrophoresis, coagu-
logram, tumour markers, urinanlysis, were all within
normal limits. We suspected he had developed a meta-
static disease because the patient had a history of pri-
mary spinal melanoma. Chest radiography showed a
right hilar lymphadenopathy and pulmonary metastatic
lesions. Pelvis and thoracolumbosacral plain radiographs
revealed multiple metastatic lesions. Tc-99 m bone scin-
tigraphy showed increased osteoblastic activity, which
predominantly affected the axial skeleton. (Figure 2).
Transiliac crest core bone biopsy showed tumour tissue
composed of large melanocytes with prominent nucleoli,
which makes up 90% of all bone marrow cells (Figure
1C and 1D). Immunohystochemically, tumour cells give
a positive reaction to Melan-A and HMB-45 consistent
with the diagnosis of metastatic melanoma (Figure 1E
and 1F). A staging contrast enhanced multislice
Figure 1 Histopathological evaluation. Hematoxylin and eosin
histologic analysis revealed a highly cellular malignant tumour with
prominent nucleoli (image A 100×, images B and C 200×, image D
400×). Immunohistochemical study shows that the tumour cells
stained diffusely positive for Melan-A and HMB-45, consistent with
the diagnosis of melanoma (images E 200×, image F 400×).
Figure 2 Bone scintigraphy.B o n es c i n t i g r a p h yw i t hT c - 9 9m
demonstrates extensive osteoblastic activity, predominantly located
in the axial skeleton within the spine, pelvis and ribs.
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and pelvis revealed stage-IV melanoma with thoracic
lymphadenopathy, multiple osteolytic lesions and
numerous metastases within lung parenchyma, liver and
spleen (Figure 3C-3G). The control magnetic resonance
imaging (MRI) of the thoracic spine showed no recur-
rence of the primary process (Figure 3A and 3B). The
patient was seen by a medical oncologist with a view to
chemotherapy. We have decided to start with Dart-
mouth regimen (dacarbazine, cisplatin, carmustine, and
tamoxifen) which has been reported to induce major
tumour responses in 40% to 50% of stage-IV melanoma
patients [6]. He has received only three cycles of Dart-
mouth regimen and he tolerated the treatment very
well. Unfortunately, during his next hospitalization he
died as a result of febrile neutropenia, sepsis and multi-
ple organ failure.
Discussion
Melanomas could occur in any tissue in which melano-
cytes can normally be found. Primary spinal melanomas
are exceedingly rare malignant tumours whose origin
can be illustrated by embriology. In 1859, Virchow
showed that primary melanomas of the CNS developed
from melanocytes located in the leptomeninges. Mela-
noblasts, the precursors of melanocytes are belived to be
derived from the neural crest during early embrionic
development. The presence of melanocytes in neural tis-
sue can be explained by the fact that these melanocytes
accompany blood vessels to the leptomeninges and can
proliferate in the neural parenchyma [4,7]. They can
also be precursors to benign melanocytoma, pigmented
schwannoma and pigmented medulloblastoma, which is
relevant for differential diagnosis [4,8]. A big difficulty
when discussing melanoma of the CNS is to decide
which cases represent primary growths and which are
metastatic disease. In general, melanocytic mass in the
CNS is known to be the result of metastasis. Only after
detailed clinical work-up including dermatological, oph-
talmological and endoscopic examination, a solitary mel-
anotic lesion of the CNS can be identified as a primary
tumour. The following criteria should also be consid-
ered: no melanoma tumour outside the CNS and invol-
vement of the meninges and/or neural tissue [5]. In all
cases of primary spinal melanoma, the clinical presenta-
tion suggests progressive spinal cord compression with
clinical signs and symptoms of compressive myelopathy.
The neurosurgical treatment is the method of choice,
but in some cases where surgery is not possible, radio-
therapy also may be used. Larson et al. [9] showed an
average life expectancy of approximately seven years
after surgery with radiotherapy. As opposed to that, the
survival time with melanoma of the skin with metastases
to CNS was only six months [9]. Considering the well-
known metastazing potential of melanomas, it may seem
surprising that primary CNS melanomas do not spread
for a long time and may have a favourable outcome
after complete neurosurgical excision. Clinically, this is
the main reason why distinction between primary and
metastatic melanoma is important. In the present case,
progression of melanoma was controlled for 17 years,
which is an unusually long time. The key factor in this
successful, long survival remains unclear. The character-
istics of the CNS probably contribute to the nature of
this disease and contrary to melanoma of the skin, lym-
phatic spread would be impossible because there are no
lymphatic vessels in the neural tissue. The blood-brain
barrier of the neural parenchyma probably also prevents
the hematogenous spreading.
At present, MRI has a leading diagnostic role in
patients with serious spinal pathology but distinction of
tumour type based on MRI findings remains difficult.
The MRI findings of melanoma vary deeply depending
on the amount of melanin-containing cells and on the
presence or absence of hemorrhage [10,11]. The para-
magnetic effect that derives from the presence of
organic radicals from melanin is responsible for hyperin-
tensity on T1 weighted images and hypointensity on T2
weighted images. Although MRI is the primary imaging
modality in diagnosis of spinal tumors, histopathologic
diagnosis is required to differentiate benign pathologies
from malignant disease. Bony metastases of melanoma
exhibit a predilection to spread in the axial skeleton
with an incidence of 70-86% [12]. Plain radiography
findings of bony metastasis of melanoma are ostelytic
lesions, which can not be distinguished from other
osteolytic metastases on the basis of imaging criteria.
Figure 3 Radiological evaluation. Magnetic resonance sagittal T2
weighted image (image A) and postcontrast sagittal T1 image
(image B) of the thoracic spine shows millimetric hyperintense
metastases with no residual-recurrent tumor. Multislice computed
tomography of the chest and abdomen demonstrated osteolytic
(image G) and parenchymal metastases (arrows) in lungs (images C
and D), liver and spleen (images E and F).
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identify approximately 40% of metastatic bone lesions
[13]. Radionuclide imaging of bone marrow metastases
with a Tc-99 m is very effective, simple and safe method
for the detection of melanoma metastases or recurrent
disease [12]. Bone scans remain the study of choice for
initial screening, because of their overall sensitivity,
lower cost and ability to assess the entire body conveni-
ently [12]. Since computed tomography (CT) facilitates
simultaneous examination of multiple sites at risk for
metastatic disease and may allow earlier detection of
metastatic disease, CT is being used with an increasing
frequency for clinical staging of melanoma. It is also
being used to monitor clinical response of patients to
different therapy [14]. Whole body positron-emission
tomography-CT (PET-CT) was found to be capable of
uncovering metastases not seen with conventional CT
alone and could also be used for initial staging [15].
Thus, the ultimate diagnosis can only be made on the
basis of histopathological and immunohystochemical
examination.
Melanoma is considered a relatively radioresistant
tumour [16]. However, some studies have shown that
patients with spinal cord compression may achieve
shrinkage of the tumor with radiation therapy [17,18].
Radiotherapy is reserved for palliation of symptoms due
to local tumour growth [16], as sole decompressive
modality or as an adjuvant to laminectomy [19,20]. Irra-
diation regimens should be selected on the basis of
patient long-term or short-term prognosis, and on
spinal cord tolerance which limits the utilisation of high
dose per fraction schedules (30 Gy at 2-3 Gy per day in
15-20 days). In 1995, Hamilton and colleagues [21] first
described the use of linear-accelerator-based spinal
stereotactic radiosurgery. Most radiosurgical depart-
ments currently utilize doses of 12-24 Gy to the margin
of the treatment volume and deliver spinal radiosurgery
in 1-5 fractions [22,23]. The prescription dose depends
in part upon the tumor location and volume as well as
the fractionation scheme, surrounding organs at risk,
and prior radiotherapy.
Melanoma has also been refractory to most standard
systemic therapy for decades. Single-agent or combina-
tion chemotherapy drugs in use at this time are of lim-
ited value. The two approved treatments, dacarbazine
and interleukin-2, have not demonstrated an impact
on overall survival. Some novel regimens (multiagent
chemotherapy, biochemotherapy, biotherapy with
interferon-g and interferon-a, antisense bcl-2 oligonu-
cleotide oblimersen, a reactive-oxide species inhibitor
or a combined approach) [20-31] have also not signifi-
cantly impacted overall survival [32]. However, evi-
dence of tumor regression with prolonged time to
progression has been seen in patients with melanoma
who received cytotoxic T lymphocyte antibodies
(CTLA-4) [33]. Combination of chemotherapy and/or
new monoclonal antibody that overcomes CTLA-4-
mediated T-cell suppression (ipilimumab) improved
o v e r a l ls u r v i v a l[ 3 4 , 3 5 ] .P h a s e1a n d2c l i n i c a lt r i a l so f
the BRAF kinase inhibitor vemurafenib produced
improved rates of overall and progression-free survival
in patients with previously untreated melanoma with
the BRAF V600E mutation [36]. Our understanding of
the biology of melanoma is steadily increasing and
t h e r ew i l lb ean u m b e ro fn e wa g e n t si nt h ef u t u r e
which have already entered clinical trials and are pro-
mising combined approaches targeting melanoma by
different molecular mechanisms.
Finally, early detection of melanoma through patient
education regarding clinical characteristics of melanoma,
counselling on the risk of developing a metastatic
tumor, self-examination and medical examination con-
tinues to be of the utmost importance. During mela-
noma follow-up, patients are clinically monitored in
order to detect a relapse. There is currently no scientific
consensus on the frequency of follow-up after initial
surgical treatment and the use of imaging techniques.
Typically patients will be seen every 3-6 months during
the first 3 years and every 6-12 months thereafter. Rou-
tine laboratory tests, tumor markers (S 100B, tyronsi-
nase), ultrasound of lymph nodes, chest radiography, CT
or whole body PET/PET-CT scans may be used in the
follow-up of patients with primary melanoma or follow-
ing treatment of metastases [37,38].
Conclusion
This case remind us how little we truly know about the
biological behavior of melanoma and the patient’s inher-
ent biological response to the tumor. It is important to
know that in all cases of back ore skeletal pain and
unexplained weight loss, malignancy must always be
considered in the differential diagnosis, especially in the
subjects with a positive medical history. Patients who
have back, skeletal, or joint pain that is unresponsive to
a few weeks of conservative treatment or have known
risk factors with or without serious etiology, are candi-
dates for imaging studies.
Melanomas are unpredictable tumours with a different
clinical course. The present case also demonstrates that
complete resection alone may result in a favourable out-
come, but regular medical follow-up for an extended
period, patient education and councelling with the pur-
pose of an early detection of a metastatic disease, is
highly recommended.
Consent
Written informed consent was obtained from the patient
for publication of this Case report and any
Katalinic et al. World Journal of Surgical Oncology 2011, 9:150
http://www.wjso.com/content/9/1/150
Page 4 of 6accompanying images. A copy of the written consent is
available for review by the Editor-in-Chief of this
journal.
Abbreviations
CNS: central nervous system; MSCT: multislice computed tomography; MRI:
magnetic resonance imaging (MRI); CT: computed tomography; PET-CT:
positron-emission tomography; Gy: gray; CTLA-4: cytotoxic T lymphocyte
antibodies; BRAF: proto-oncogene BRAF
Acknowledgements
The Authors wish to thank Mr. Kristijan Nikolic and Mr. Marko Cip for
technical suggestions in preparation of this manuscript.
Author details
1Department of Oncology, University Hospital Centre (KBC Zagreb),
University of Zagreb School of Medicine, Zagreb, Croatia.
2Department of
Clinical Immunology and Rheumatology, University Hospital Centre (KBC
Zagreb), University of Zagreb School of Medicine, Zagreb, Croatia.
3Department of Diagnostic and Interventional Radiology, University Hospital
Centre (KBC Zagreb), University of Zagreb School of Medicine, Zagreb,
Croatia.
4Department of Pathology and Cytology, University Hospital Centre
(KBC Zagreb), University of Zagreb School of Medicine, Zagreb, Croatia.
Authors’ contributions
DK, BA and MM carried out the study design and writing. MS and NC
participated in the data collection and interpretation and drafted the
manuscript. RSP, KZ and SD participated in the design of the study and the
figure design. SP participated in the literature search and helped to draft the
manuscript. All authors read and approved the final manuscript.
Competing interests
Each coauthor certifies that he ore she has no commercial association that
might pose a conflict of interest in connection with the submitted article.
Received: 8 July 2011 Accepted: 17 November 2011
Published: 17 November 2011
References
1. Diepgen TL, Mahler V: The epidemiology of skin cancer. Br J Dermatol
2002, 146:1-6.
2. Kounin GK, Romansky KV, Traykov LD, Shotekov PM, Stoilova DZ: Primary
spinal melanoma with bilateral papilledema. Clin Neurol Neurosurg 2005,
107:525-527.
3. Naing A, Messina JL, Vrionis FR, Daud AI: Uncommon manifestations of
common malignancies: case 3. Malignant melanoma arising from a
spinal nerve root. J Clin Oncol 2004, 22:3194-3195.
4. Brat DJ, Giannini C, Scheithauer BW, Burger PC: Primary melanocytic
neoplasms of the central nervous system. Am J Surg Pathol 1999,
23:745-754.
5. Hayward RD: Malignant melanoma and the central nervous system. J
Neurol Neurosurg Psychiatry 1976, 39:526-530.
6. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS,
Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, Houghton AN,
Kirkwood JM: Phase III Multicenter Randomized Trial of the Dartmouth
Regimen Versus Dacarbazine in Patients With Metastatic Melanoma. J
Clin Oncol 1999, 17:2745-2751.
7. Yamasaki T, Kikuchi H, Yamaschita J, Asato R, Fujita M: Primary spinal
intramedullary malignant melanoma: case report. Neurosurgery 1989,
25:117-121.
8. Farrokh D, Fransen P, Faverly D: MR findings of a primary intramedullary
malignant melanoma: case report and literature review. Am J Neuroradiol
2001, 22:1864-1866.
9. Larson TC, Houser OW, Onofrio BM, Peipgras DG: Primary spinal
melanoma. J Neurosurg 1987, 66:47-49.
10. Isiklar I, Leeds NE, Fuller GN, Kumar AJ: Intracranial metastatic melanoma:
correlation between MR imaging characteristics and melanin content.
Am J Roentgenol 1995, 165:1503-1512.
11. Woodruff WW, Djang WT, McLendon RE, Heinz ER, Voorhees DR:
Intracerebral malignant melanoma: high-field-strength MR imaging.
Radiology 1987, 165:209-213.
12. Fon GT, Wong WS, Gold RH, Kaiser LR: Skeletal metastases of melanoma:
radiographic, scintigraphic, and clinical review. Am J Roentgenol 1981,
137:103-108.
13. Edelstyn GA, Gillespie PJ, Grebell ES: The radiologic demonstration of
osseous metastases: experimental observations. Clin Radiol 1967,
18:158-164.
14. Patten RM, Shuman WP, Teefey S: Metastases from malignant melanoma
to the axial skeleton: a CT study of frequency and appearance. Am J
Roentgenol 1990, 155:109-112.
15. Finger PT, Kurli M, Wesley P, Tena L, Kerr KR, Pavlick A: Whole body PET/CT
imaging for detection of metastatic choroidal melanoma. Br J
Ophthalmol 2004, 88:1095-1097.
16. Bhatia S, Tykodi SS, Thompson JA: Treatment of metastatic melanoma: an
overview. Oncology 2009, 23:488-496.
17. Rate WR, Solin LJ, Turrisi AT: Palliative radiotherapy for metastatic
malignant melanoma: brain metastases, bone metastases, and spinal
cord compression. Int J Radiot Oncol Biol Phys 1988, 15:859-864.
18. Herbert SH, Solin Lj, Rate WR, Schultz DJ, Hanks GE: The effect of palliative
radiation therapy on epidural compression due to metastatic malignant
melanoma. Cancer 1991, 67:2472-2476.
19. Cooper JS: The evolution of the role of radiation therapy in the
management of mucocutaneous malignant melanoma. Hematol Oncol
Clin North Am 1998, 12:849-862.
20. Geara FB, Ang KK: Radiation therapy for malignant melanoma. Surg Clin
North Am 1996, 76:1383-1398.
21. Hamilton AJ, Lulu BA, Fosmire H, Stea B, Cassady JR: Preliminary clinical
experience with linear accelerator-based spinal stereotactic radiosurgery.
Neurosurgery 1995, 36:311-319.
22. Gerszten PC: The role of minimally invasive techniques in the
management of spine tumors: percutaneous bone cement
augmentation, radiosurgery, and microendoscopic approaches. Orthop
Clin North Am 2007, 38:441-450.
23. Gerszten PC, Ozhasoglu C, Burton SA, Vogel WJ, Atkins BA, Kalnicki S,
Welch WC: CyberKnife frameless stereotactic radiosurgery for spinal
lesions: clinical experience in 125 cases. Neurosurgery 2004, 55:89-99.
24. Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH: Phase
III trial of dacarbazine versus dacarbazine with interferon alpha-2b
versus dacarbazine with tamoxifen versus dacarbazine with interferon
alpha-2b and tamoxifen in patients with metastatic malignant
melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol
1998, 16:1743-1751.
25. Demchak PA, Mier JW, Robert NJ, O’Brien K, Gould JA, Atkins MB:
Interleukin-2 and high-dose cisplatin in patients with metastatic
melanoma: a pilot study. J Clin Oncol 1991, 9:1821-1830.
26. Flaherty LE, Robinson W, Redman BG, Gonzalez R, Martino S, Kraut M,
Valdivieso M, Rudolph AR: A phase II study of dacarbazine and cisplatin
in combination with outpatient administered interleukin-2 in metastatic
malignant melanoma. Cancer 1993, 71:3520-3525.
27. Atkins MB, O’Boyle KR, Sosman JA, Weiss GR, Margolin KA, Ernest ML,
Kappler K, Mier JW, Sparano JA, Fisher RI: Multiinstitutional phase II trial of
intensive combination chemoimmunotherapy for metastatic melanoma.
J Clin Oncol 1994, 12:1553-1560.
28. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM,
Topalian SL, Seipp CA, Einhorn JH, White DE, Steinberg SM: Prospective
randomized trial of the treatment of patients with metastatic melanoma
using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or
in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol
1999, 17:968-975.
29. Huncharek M, Caubet JF, McGarry R: Single-agent DTIC versus
combination chemotherapy with or without immunotherapy in
metastatic melanoma: a meta-analysis of 3273 patients from 20
randomized trials. Melanoma Res 2001, 11:75-81.
30. Wöll E, Bedikian A, Legha SS: Uveal melanoma: natural history and
treatment options for metastatic disease. Melanoma Res 1999, 9:575-581.
31. O’Day SJ, Kim CJ, Reintgen DS: Metastatic Melanoma: Chemotherapy to
Biochemotherapy. Cancer Control 2002, 9:31-38.
32. O’Day SJ, Atkins MB, Boasberg P, Wang HJ, Thompson JA, Anderson CM,
Gonzalez R, Lutzky J, Amatruda T, Hersh EM, Weber JS: Phase II multicenter
Katalinic et al. World Journal of Surgical Oncology 2011, 9:150
http://www.wjso.com/content/9/1/150
Page 5 of 6trial of maintenance biotherapy after induction concurrent
Biochemotherapy for patients with metastatic melanoma. J Clin Oncol
2009, 27:6207-6212.
33. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ,
Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA,
Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA: Cancer
regression and autoimmunity induced by cytotoxic T lymphocyte-
associated antigen 4 blockade in patients with metastatic melanoma.
Proc Natl Acad Sci USA 2003, 100:8372-8377.
34. Robert C, Thomas L, Bondarenko I, O’Day S, MD JW, Garbe C, Lebbe C,
Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A,
Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S,
Chen TT, Humphrey R, Hoos A, Wolchok JD: Ipilimumab plus dacarbazine
for previously untreated metastatic melanoma. N Engl J Med 2011,
364:2517-2526.
35. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB,
Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den
Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D,
Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS,
Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ: Improved survival with
ipilimumab in patients with metastatic melanoma. N Engl J Med 2010,
363:711-23.
36. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J,
Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C,
Jouary T, Schadendorf D, Ribas A, O’Day SJ, Sosman JA, Kirkwood JM,
Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT,
McArthur GA, BRIM-3 Study Group: Improved survival with vemurafenib in
melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
37. Machet L, Perrinaud A, Giraudeau B: Routine ultrasonography in
melanoma follow-up? The Lancet Oncology 2005, 6:2.
38. DiFronzo LA, Wanek LA, Morton DL: Earlier diagnosis of second primary
melanoma confirms the benefits of patient education and routine
postoperative follow-up. Cancer 2001, 91:1520-1524.
doi:10.1186/1477-7819-9-150
Cite this article as: Katalinic et al.: Low back pain as the presenting sign
in a patient with primary extradural melanoma of the thoracic spine - A
metastatic disease 17 Years after complete surgical resection. World
Journal of Surgical Oncology 2011 9:150.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Katalinic et al. World Journal of Surgical Oncology 2011, 9:150
http://www.wjso.com/content/9/1/150
Page 6 of 6